BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 31445233)

  • 61. Aryl/heteroaryl Substituted Celecoxib Derivatives as COX-2 Inhibitors: Synthesis, Anti-inflammatory Activity and Molecular Docking Studies.
    Madhava G; Ramana KV; Sudhana SM; Rao DS; Kumar KH; Lokanatha V; Rani AU; Raju CN
    Med Chem; 2017; 13(5):484-497. PubMed ID: 28228088
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel benzenesulfonamide and 1,2-benzisothiazol-3(2H)-one-1,1-dioxide derivatives as potential selective COX-2 inhibitors.
    Taher ES; Ibrahim TS; Fares M; Al-Mahmoudy AMM; Radwan AF; Orabi KY; El-Sabbagh OI
    Eur J Med Chem; 2019 Jun; 171():372-382. PubMed ID: 30928709
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Synthesis of new ibuprofen hybrid conjugates as potential anti-inflammatory and analgesic agents.
    Panda SS; Girgis AS; Honkanadavar HH; George RF; Srour AM
    Future Med Chem; 2020 Aug; 12(15):1369-1386. PubMed ID: 32689823
    [No Abstract]   [Full Text] [Related]  

  • 64. Molecular docking design and one-pot expeditious synthesis of novel 2,5-diarylpyrazolo[1,5-a]pyrimidin-7-amines as anti-inflammatory agents.
    Aggarwal R; Singh G; Kaushik P; Kaushik D; Paliwal D; Kumar A
    Eur J Med Chem; 2015 Aug; 101():326-33. PubMed ID: 26160113
    [TBL] [Abstract][Full Text] [Related]  

  • 65. COX-1/COX-2 inhibition assays and histopathological study of the new designed anti-inflammatory agent with a pyrazolopyrimidine core.
    Abdelall EKA; Lamie PF; Ahmed AKM; El-Nahass ES
    Bioorg Chem; 2019 May; 86():235-253. PubMed ID: 30716621
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity.
    Bansal S; Bala M; Suthar SK; Choudhary S; Bhattacharya S; Bhardwaj V; Singla S; Joseph A
    Eur J Med Chem; 2014 Jun; 80():167-74. PubMed ID: 24780593
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Investigations of new pyridazinone derivatives for the synthesis of potent analgesic and anti-inflammatory compounds with cyclooxygenase inhibitory activity.
    Okçelik B; Unlü S; Banoglu E; Küpeli E; Yeşilada E; Sahin MF
    Arch Pharm (Weinheim); 2003 Sep; 336(9):406-12. PubMed ID: 14528488
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Synthesis of new hexahydropyrimido[1,2-
    Hassanein HH; Abdel Rahman DE; Fouad MA; Ahmed RF
    Future Med Chem; 2021 Apr; 13(7):625-641. PubMed ID: 33624540
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies.
    Rashad AY; Kassab SE; Daabees HG; Abdel Moneim AE; Rostom SAF
    Bioorg Chem; 2021 Aug; 113():104948. PubMed ID: 34052736
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of anti-inflammatory, analgesic activities, and side effects of some pyrazole derivatives.
    Domiati S; El-Mallah A; Ghoneim A; Bekhit A; El Razik HA
    Inflammopharmacology; 2016 Aug; 24(4):163-72. PubMed ID: 27342269
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novel tetrazole and cyanamide derivatives as inhibitors of cyclooxygenase-2 enzyme: design, synthesis, anti-inflammatory evaluation, ulcerogenic liability and docking study.
    Lamie PF; Philoppes JN; Azouz AA; Safwat NM
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):805-820. PubMed ID: 28587532
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of in vivo anti-inflammatory and analgesic activities of novel derivatives of Ugi-4CR.
    Mohanram I; Meshram J
    Mini Rev Med Chem; 2013 Aug; 13(10):1508-15. PubMed ID: 23815582
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidines as anti-inflammatory agents.
    Tageldin GN; Fahmy SM; Ashour HM; Khalil MA; Nassra RA; Labouta IM
    Bioorg Chem; 2018 Aug; 78():358-371. PubMed ID: 29627656
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synthesis of novel 1,2,3-triazole based benzoxazolinones: their TNF-α based molecular docking with in-vivo anti-inflammatory, antinociceptive activities and ulcerogenic risk evaluation.
    Haider S; Alam MS; Hamid H; Shafi S; Nargotra A; Mahajan P; Nazreen S; Kalle AM; Kharbanda C; Ali Y; Alam A; Panda AK
    Eur J Med Chem; 2013; 70():579-88. PubMed ID: 24211633
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Visnagin and benzofuran scaffold-based molecules as selective cyclooxygenase-2 inhibitors with anti-inflammatory and analgesic properties: design, synthesis and molecular docking.
    Khalil HS; Sedky NK; Amin KM; Abd Elhafez OM; Arafa RK
    Future Med Chem; 2019 Apr; 11(7):659-676. PubMed ID: 30958028
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives.
    Li MH; Yin LL; Cai MJ; Zhang WY; Huang Y; Wang X; Zhu XZ; Shen JK
    Acta Pharmacol Sin; 2005 Jul; 26(7):865-72. PubMed ID: 15960895
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase-2 inhibitors.
    Chen QH; Rao PN; Knaus EE
    Bioorg Med Chem; 2005 Dec; 13(23):6425-34. PubMed ID: 16099663
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Insight on novel oxindole conjugates adopting different anti-inflammatory investigations and quantitative evaluation.
    Said MF; Marie SM; Mohamed NM; Mahrouse MA; Moussa BA
    Future Med Chem; 2024; 16(9):817-842. PubMed ID: 38634318
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel 4-methylsulfonylphenyl derivatives as NSAIDS with preferential COX-2 inhibition.
    Amin NH; Mohammed AA; Abdellatif KR
    Future Med Chem; 2018 Jan; 10(1):53-70. PubMed ID: 29235887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.